Format

Send to

Choose Destination
J Formos Med Assoc. 2019 Aug 13. pii: S0929-6646(19)30259-1. doi: 10.1016/j.jfma.2019.07.021. [Epub ahead of print]

High prevalence of genotype 6 hepatitis C virus infection in Southern Taiwan using Abbott genotype assays.

Author information

1
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan. Electronic address: jjchen@mail.chimei.org.tw.
2
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
3
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Yongkang, Tainan, Taiwan.
4
Department of Pathology, Chi-Mei Medical Center, Liouying, Tainan, Taiwan.
5
Department of Clinical Pathology, Chi-Mei Medical Center, Yongkang, Tainan, Taiwan; Institute of Biomedical Science, National Sun Yat-sen University, Kaohsiung, Taiwan.
6
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Hospital, Chiali, Tainan, Taiwan.

Abstract

BACKGROUND/PURPOSE:

Abbott RealTime Genotype II assay can effectively identify hepatitis C virus (HCV) genotypes (GTs), but some GT 6 subtypes might not be differentiated from GT 1. Abbott RealTime Genotype II PLUS and sequencing might be needed to resolve these ambiguous results. Unlike the high prevalence of GT 6 in Southeast Asia, GT 6 had rarely been reported in Taiwan except in intravenous drug abusers (IDU). But the prevalence of GT 6 in Taiwan might be underestimated. We conducted this study to determine the GTs in a HCV endemic area in Southern Taiwan.

METHODS:

A total of 1147 patients with hepatitis C viremia for direct acting antivirals (DAA) treatment at the Chi Mei medical system in Tainan were enrolled. Genotype was determined using a working flow consisted of Abbott GT II, PLUS assays and 5' untranslated region (5' UTR)/core sequencing.

RESULTS:

Among the 1147 patients, 883 (77.0%) obtained GT results by GT II, 264 (23.0%) samples with ambiguous results by GT II assay received further tests, including 194 (73.5%) with PLUS assay and 70 (26.5%) with 5'UTR/core sequencing. Nearly three-quarters (73.5%) of ambiguous results by GT II assay were GT 6. Overall, 18.3% of samples were GT 6. Phylogenetic study of 11 samples of GT 6 subtypes showed 7 (63.6%) were 6 g.

CONCLUSIONS:

GT 6 is the major factor for high ambiguous rate by GT II. Unexpected high prevalence of GT 6 (18.3%) in Southern Taiwan, especially subtype 6 g, closely related to Indonesian strains, is first reported.

KEYWORDS:

Direct acting antiviral; Genotype 6; Genotype assay; Hepatitis C

PMID:
31420113
DOI:
10.1016/j.jfma.2019.07.021
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center